Institutions / Merck & Co., Inc. / Activity
Activity — Merck & Co., Inc.
12 moves.
| Date | Action | Company | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|
| Q2 2026 as of | New | AKTS Aktis Oncology, Inc. Common Stock | $30.71M | +953K | 952,844 5.83% of portfolio | medium |
| Q2 2026 as of | New | Eikon Therapeutics, Inc. Common stock | $21.75M | +1.7M | 1,666,666 4.13% of portfolio | medium |
| Q2 2026 as of | Exit | 29384C908 Common stock | $-17.88M | -1.7M -100.00% | 0 | medium |
| Q2 2026 as of | New | TRDA Entrada Therapeutics, Inc. Common Stock | $12.80M | +1.7M | 1,739,768 2.43% of portfolio | medium |
| Q2 2026 as of | New | Sutro Biopharma, Inc. Common stock | $9.04M | +272K | 272,351 1.72% of portfolio | medium |
| Q2 2026 as of | Exit | 29970R204 Common stock | $-5.79M | -1.2M -100.00% | 0 | medium |
| Q2 2026 as of | New | EVAX Evaxion A/S ADR | $3.76M | +1.2M | 1,214,126 0.71% of portfolio | low |
| Q2 2026 as of | Exit | Sutro Biopharma, Inc. Common stock | $-3.15M | -272K -100.00% | 0 | low |
| Q2 2026 as of | New | XLO Xilio Therapeutics, Inc. Common Stock | $1.02M | +106K | 105,982 0.19% of portfolio | low |
| Q2 2026 as of | Exit | 98422T100 Common stock | $-949.9K | -1.5M -100.00% | 0 | low |
| Q2 2026 as of | Exit | 14216R101 Common stock | $-63.3K | -1.5M -100.00% | 0 | low |
| Q2 2026 as of | Add | HURA TuHURA Biosciences, Inc./NV Common Stock | $12.9K | +5K +39.39% | 19,445 <0.01% of portfolio | low |